Table 1.
Clinical and laboratory characteristics of 248 patients with blast phase myeloproliferative neoplasms at the time of leukemic transformation
| Variables | All patients (n = 248) | Post-PMF AML (n = 118) | Post-PV/ET AMLa (n = 130) | P-value |
|---|---|---|---|---|
| Age in years; median (range) | 67 (40–90) | 67 (40–87) | 68 (42–90) | 0.3 |
| Age > 65 years; n (%) | 140 (56) | 63 (53) | 77 (59) | 0.4 |
| Sex (male); n (%) | 161 (65) | 84 (71) | 77 (59) | 0.04 |
| Transfusion dependent; n (%) “N” evaluable = 233 | 80 (34) | 51 (46) | 29 (24) | 0.0004 |
| Hemoglobin, g/dl; median (range) “N” evaluable = 217 | 9.3 (0.7–18.1) | 9 (6.1–13.7) | 9.5 (0.7–18.1) | 0.05 |
| Platelets x 109/L; median (range) “N” evaluable = 216 | 78 (3–2051) | 69 (4–670) | 100 (3–2051) | 0.004 |
| Platelets < 100 × 109/L; n (%) “N” evaluable = 216 | 126 (58) | 68 (69) | 58 (50) | 0.004 |
| Leukocytes x 109/L; median (range) “N” evaluable = 218 | 15.9 (0.4–600) | 22.2 (0.5–154) | 14.3 (0.4–600) | 0.09 |
| Leukocytes > 25 × 109/L; n (%) “N” evaluable = 218 | 81 (37) | 42 (42) | 39 (33) | 0.2 |
| Circulating blasts %; median (range) “N” evaluable = 215 | 26 (0–99) | 29 (1–99) | 22 (0–89) | 0.005 |
| Circulating blasts ≥ 20%; n (%) “N” evaluable = 215 | 152 (71) | 77 (77) | 75 (65) | 0.06 |
| Bone marrow blasts %; median (range) “N” evaluable = 180 | 33 (1–97) | 36 (2–97) | 30 (1–91) | 0.09 |
| Bone marrow blasts ≥ 20%; n (%) “N” evaluable = 180 | 156 (87) | 64 (86) | 92 (87) | 0.9 |
| ANC, x 109/L; median (range) “N” evaluable = 207 | 4.9 (0–68.9) | 5.4 (0–56.1) | 4.3 (0.1–68.9) | 0.98 |
| AMC, x 109/L; median (range) “N” evaluable = 204 | 0.7 (0–36.2) | 0.7 (0–25.3) | 0.7 (0–36.2) | 0.45 |
| Karyotype “N” evaluable = 172 Normal; n (%) Abnormal; n (%) | 32 (19) 140 (81) | 18 (23) 59 (77) | 14 (15) 81 (85) | 0.3 |
| JAK2 mutated; n (%) “N” evaluable = 144 | 98 (68) | 35 (60) | 63 (73) | 0.1 |
| Allogeneic stem cell transplant; n (%) | 24 (11) | 9 (8) | 15 (13) | 0.3 |
| Follow up in months; median (range) | 3.6 (0–122) | 3.3 (0–72) | 4 (0–122) | 0.7 |
| Deaths; n (%) | 239 (96) | 115 (97) | 124 (95) | 0.4 |
AML acute myeloid leukemia, PMF primary myelofibrosis, PV polycythemia vera, ET essential thrombocythemia, ANC absolute neutrophil count, AMC absolute monocyte count, JAK2 Janus kinase 2
a Post PV AML patients, N = 60
Post PV AML without myelofibrosis phase, N = 32
Post PV AML with myelofibrosis phase, N = 28
Post ET AML patients, N = 70
Post ET AML without myelofibrosis phase, N = 39
Post ET AML with myelofibrosis phase, N = 31